Pujols Mayobanex 4
4 · Kyverna Therapeutics, Inc. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Kyverna (KYTX) CTO Pujols Mayobanex Receives 300,000-Share Award
What Happened
Pujols Mayobanex, Chief Technology Officer of Kyverna Therapeutics (KYTX), received a derivative equity award on February 9, 2026 for 300,000 shares. The reported acquisition price is $0.00 (derivative award/option), resulting in no immediate cash outlay. This was a grant of equity compensation rather than an open-market buy or sell.
Key Details
- Transaction date: 2026-02-09; Form 4 filed: 2026-02-11 (timely filing).
- Transaction type/code: Award/Grant (derivative) — Code A.
- Shares/options granted: 300,000; reported acquisition price: $0.00.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Vesting footnote: 1/4 vests on Feb 9, 2027, then 1/48 of the total shares vests each month thereafter, subject to continuous service.
- No immediate sale or exercise reported in this filing.
Context
This filing documents an equity compensation grant (an option-type award) that aligns the executive's interests with shareholders but is not a market purchase or sale. The award vests over a typical one-year cliff then monthly schedule (four-year total), and there is no indication in this filing of any immediate exercise or cashless transaction.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-02-09+300,000→ 300,000 totalExercise: $8.08Exp: 2036-02-09→ Common Stock (300,000 underlying)
Footnotes (1)
- [F1]1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive